ZAGREB, Feb 17 (Hina) - Croatia's pharmaceutical company Pliva and the Sanofi Biocom Pharma Holding B.V. from the Netherlands on Wednesday signed an agreement on the purchase of 60 per cent of a Polish pharmaceutical company's stock.
The investment into Farmacom Sp. stock amounts to US$4.8 million, paid in cash, Pliva reported. The completion of the transaction is conditional upon the approval of the Polish office for the protection of market competition, and is expected in early spring. The purchase will be realised through Pliva's subsidiary Pliva Krakow S.A., which owns the remaining 40 per cent of Farmacom stock. The transaction gives Pliva an excellent opportunity to consolidate its position in the region, Pliva's Management Board chairman Zeljko Covic said, adding the investment in Farmacom was an important step towards the establishment of a manufacture portfolio. Farma
ZAGREB, Feb 17 (Hina) - Croatia's pharmaceutical company Pliva and
the Sanofi Biocom Pharma Holding B.V. from the Netherlands on
Wednesday signed an agreement on the purchase of 60 per cent of a
Polish pharmaceutical company's stock.
The investment into Farmacom Sp. stock amounts to US$4.8 million,
paid in cash, Pliva reported.
The completion of the transaction is conditional upon the approval
of the Polish office for the protection of market competition, and
is expected in early spring.
The purchase will be realised through Pliva's subsidiary Pliva
Krakow S.A., which owns the remaining 40 per cent of Farmacom
stock.
The transaction gives Pliva an excellent opportunity to
consolidate its position in the region, Pliva's Management Board
chairman Zeljko Covic said, adding the investment in Farmacom was
an important step towards the establishment of a manufacture
portfolio.
Farmacom manufactures, develops and markets a spectre of high
quality medications in all forms - pills, capsules and syrups.
(hina) it jn/lml